Somerset, N.J. – May 2, 2014 Mr. Michael Valazza, R.Ph., Vice President of Advanced Delivery Technologies, at Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, is to present at the Curtis & Coulter Controlled & Modiﬁed Drug Release Conference, which takes place from May 7th to 8th at the Sheraton Philadelphia University City Hotel, Philadelphia, PA.
His presentation, “Advanced Techniques for Enabling Better Treatments Through Oral Drug Delivery,” takes place on Thursday May 8th at 9.30 a.m., and will cover how new methodologies in oral drug delivery are allowing products to be developed better and more efficiently. Mr. Valazza will also be showcasing formulation and solubility solutions for challenging drug compounds that help to advance more products into the development pipeline.
Throughout his 30 year career, Mr. Valazza has held various executive positions in product development and technical services with a focus on modified and controlled release solid dosage form applications. Mr. Valazza is a member of a variety of professional organizations including the AAPS (American Association of Pharmaceutical Scientists) and the Controlled Release Society. He is a recognised leader in the field of controlled release technology and has published articles in various scientific journals and made presentations at numerous industry conferences. Mr. Valazza received a B.S. in Pharmacy from Rutgers University in 1982 and is a registered pharmacist.
To arrange a meeting with Catalent executives at the conference, please contact Richard Kerns at NEPR- firstname.lastname@example.org.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2013 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com